Beautiful Virgin Islands

Tuesday, Jul 15, 2025

Pfizer testing COVID treatment pill

Pfizer testing COVID treatment pill

Pfizer, maker of the most widely-used COVID-19 vaccine in the U.S., is testing a potential pill-based treatment for the virus using the same class of medication typically used to treat HIV.
Pfizer announced the beginning of a phase 1 clinical trial using a protease inhibitor pill as a treatment for the virus on Tuesday. News of the trial comes months after Pfizer's COVID-19 vaccine, made in collaboration with the German firm BioNTech, was approved for use and began to be administered in the U.S. and several other countries. The pill, currently dubbed PF-07321332, could offer an additional weapon against the virus as fast-moving mutations threaten to weaken the effectiveness of vaccines.

"Tackling the COVID-19 pandemic requires both prevention via vaccine and targeted treatment for those who contract the virus," Pfizer's Chief Scientific Officer Mikael Dolsten said in a statement obtained by Newsweek. "Given the way that SARS-CoV-2 is mutating and the continued global impact of COVID-19, it appears likely that it will be critical to have access to therapeutic options both now and beyond the pandemic."

"We have designed PF-07321332 as a potential oral therapy that could be prescribed at the first sign of infection, without requiring that patients are hospitalized or in critical care," added Dolsten.

The drug has shown activity against the virus that causes COVID-19 in test tube experiments, as well as activity against other types of coronaviruses, with the company saying that the results raise the possibility of "potential use to address future coronavirus threats."

Dolsten touted both the oral medication and the company's previously-developed experimental protease inhibitor treatment designed to be administered to hospitalized COVID-19 patients intravenously, which is currently undergoing phase 1b trials. Dolsten said that that two different approaches offer "the potential to create an end to end treatment paradigm that complements vaccination in cases where disease still occurs."

While none of the vaccines offer total protection against contracting the virus, they have been shown to significantly reduce infections and to be extremely effective in preventing hospitalizations and death. Treatment options could help mitigate concerns posed by the fact that some of the mutations currently making their way around the world have shown a limited amount of resistance to the vaccines, although both Pfizer and Moderna are developing booster shots or new versions of vaccines to combat emerging variants.

As of Tuesday, over 64.6 million people in the U.S. had received at least one dose of the Pfizer-BioNTech vaccine, according to the Centers for Disease Control and Prevention. Moderna's vaccine was not far behind, with around 60.9 million doses administered, while the single-dose Johnson & Johnson vaccine had gone into the arms of just under 2.5 million people.

Protease inhibitors, which block virus reproduction by binding to proteins called protease, were a class of drugs that revolutionized HIV treatment in the mid-1990s. They are key components in the multi-drug "cocktail" therapies that changed HIV from an infection that almost invariably led to AIDS and death to a condition that can typically be survived if treatments are available and used regularly. The drugs are also used against Hepatitis C infections, while researchers have investigated their use as treatments for certain types of cancer and parasitic infections.
Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
Google Secures Windsurf AI Coding Team in $2.4 Billion Licence Deal
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
South African Police Minister Suspended Amid Organised Crime Allegations
Nvidia CEO Claims Chinese Military Reluctance to Use US AI Technology
Hong Kong Advances Digital Asset Strategy to Address Economic Challenges
Australia Rules Out Pre‑commitment of Troops, Reinforces Defence Posture Amid US‑China Tensions
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
U.S. Resumes Deportations to Third Countries After Supreme Court Ruling
Excavation Begins at Site of Mass Grave for Children at Former Irish Institution
Iranian President Reportedly Injured During Israeli Strike on Secret Facility
EU Delays Retaliatory Tariffs Amid New U.S. Threats on Imports
Trump Defends Attorney General Pam Bondi Amid Epstein Memo Backlash
Renault Shares Drop as CEO Luca de Meo Announces Departure Amid Reports of Move to Kering
Senior Aides for King Charles and Prince Harry Hold Secret Peace Summit
Anti‑Semitism ‘Normalised’ in Middle‑Class Britain, Says Commission Co‑Chair
King Charles Meets David Beckham at Chelsea Flower Show
If the Department is Really About Justice: Ghislaine Maxwell Should Be Freed Now
NYC Candidate Zohran Mamdani’s ‘Antifada’ Remarks Spark National Debate on Political Language and Economic Policy
President Trump Visits Flood-Ravaged Texas, Praises Community Strength and First Responders
From Mystery to Meltdown, Crisis Within the Trump Administration: Epstein Files Ignite A Deepening Rift at the Highest Levels of Government Reveals Chaos, Leaks, and Growing MAGA Backlash
Trump Slams Putin Over War Death Toll, Teases Major Russia Announcement
Reparations argument crushed
Rainmaker CEO Says Cloud Seeding Paused Before Deadly Texas Floods
A 92-year-old woman, who felt she doesn't belong in a nursing home, escaped the death-camp by climbing a gate nearly 8 ft tall
French Journalist Acquitted in Controversial Case Involving Brigitte Macron
Elon Musk’s xAI Targets $200 Billion Valuation in New Fundraising Round
Kraft Heinz Considers Splitting Off Grocery Division Amid Strategic Review
Trump Proposes Supplying Arms to Ukraine Through NATO Allies
EU Proposes New Tax on Large Companies to Boost Budget
Trump Imposes 35% Tariffs on Canadian Imports Amid Trade Tensions
Junior Doctors in the UK Prepare for Five-Day Strike Over Pay Disputes
US Opens First Rare Earth Mine in Over 70 Years in Wyoming
Kurdistan Workers Party Takes Symbolic Step Towards Peace in Northern Iraq
Bitcoin Reaches New Milestone of $116,000
Biden’s Doctor Pleads the Fifth to Avoid Self-Incrimination on President’s Medical Fitness
Grok Chatbot Faces International Backlash for Antisemitic Content
Severe Heatwave Claims 2,300 Lives Across Europe
NVIDIA Achieves Historic Milestone as First Company Valued at $4 Trillion
Declining Beer Consumption Signals Cultural Shift in Germany
Linda Yaccarino Steps Down as CEO of X After Two Years
US Imposes New Tariffs on Brazilian Exports Amid Political Tensions
Azerbaijan and Armenia are on the brink of a historic peace deal.
Emails Leaked: How Passenger Luggage Became a Side Income for Airport Workers
Polish MEP: “Dear Leftists - China is laughing at you, Russia is laughing, India is laughing”
BRICS Expands Membership with Indonesia and Ten New Partner Countries
×